Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Dose Escalation Randomized, Double-blind, Placebo-controlled Safety and Immunogenicity Trial of the Reactivation of Pertussis Toxin Immunity With the Viaskin Epicutaneous Delivery System in Healthy Adults

Next Previous
Trial Profile

A Phase I Dose Escalation Randomized, Double-blind, Placebo-controlled Safety and Immunogenicity Trial of the Reactivation of Pertussis Toxin Immunity With the Viaskin Epicutaneous Delivery System in Healthy Adults

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pertussis acellular vaccine (Primary) ; DTaP vaccine
  • Indications Pertussis
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors DBV Technologies

    • Most Recent Events

    • 16 Sep 2018 Status changed from active, no longer recruiting to completed, according to a DBV Technologies media release.
    • 05 Sep 2018 According to a DBV Technologies media release, following the review of preliminary data released in 2017, DBV, HUG and BioNet added in cohorts 3 and 4 to receive Viaskin-PT following preparation of the skin with an epidermal laser (P.L.E.A.S.E., Pantec) before each patch application.
    • 05 Sep 2018 According to a DBV Technologies media release, this phase I, proof of concept study was conducted under the supervision of Prof. Siegrist from the Clinical Research Center of HUG in collaboration with DBV Technologies and BioNet-Asia.The Company continues to evaluate the positive proof of concept results of this study to determine potential next steps in vaccination.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top